Cadila Healthcare Ltd.
BSE: 532321 | Sector: Health care |
NSE: CADILAHC | ISIN Code: INE010B01027 |
BSE 00:00 | 08 Mar | 446.10 |
3.90 (0.88%) |
OPEN
441.10 |
HIGH
451.50 |
LOW
441.10 |
NSE 00:00 | 08 Mar | 446.20 |
3.95 (0.89%) |
OPEN
443.00 |
HIGH
451.50 |
LOW
442.00 |
OPEN | 441.10 |
PREVIOUS CLOSE | 442.20 |
VOLUME | 86925 |
52-Week high | 509.35 |
52-Week low | 212.70 |
P/E | 25.32 |
Mkt Cap.(Rs cr) | 45,667 |
Buy Price | 446.10 |
Buy Qty | 1315.00 |
Sell Price | 448.50 |
Sell Qty | 100.00 |
Cadila Healthcare Ltd. (CADILAHC) - Latest News & Headlines
-
Here is a derivative strategy for Cadila Health by Vinay Rajani of HDFC Sec
7.22 am | 15 Jan 2021 | Business Standard
The stock price of Cadila Healthcare has broken out from the consolidation which held for last three weeks
-
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost
1.11 am | 11 Jan 2021 | Business Standard
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportuni...
-
Stocks to watch: RCFL, Tata Motors, RIL, BEML, Cadila Health, Adani Green
8.39 am | 4 Jan 2021 | Business Standard
Tata Motors reported a 21 per cent increase in total vehicle sales in the domestic market to 53,430 units in December
-
Stocks to watch: Cadila Health, NIIT, BEML, Dish TV, RIL, DLF, Coal India
8.49 am | 28 Dec 2020 | Business Standard
The board of NIIT has approved buyback of 98.75 lakh equity shares of face value of Rs 2 each.
-
Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%
10.37 am | 21 Dec 2020 | Business Standard
Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the N...
-
BSE Healthcare index hits new high; Sun Pharma, Laurus Labs gain up to 5%
2.47 pm | 4 Dec 2020 | Business Standard
Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in t...
-
Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19
3.53 pm | 12 Nov 2020 | Business Standard
95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day 14, compared to 68% of ...
-
Cadila Healthcare rallies 9% on strong September quarter results
9.49 am | 3 Nov 2020 | Business Standard
In Q2FY21, Cadila's Ebitda margins improved by 370 basis points at 22.6% against 18.9% in Q2FY20.
-
Zydus Cadila Q2 net up four-fold on surge in US sales, strong show at home
6.02 pm | 2 Nov 2020 | Business Standard
Firm prunes net debt by 40% since March 2020; consolidated income up 13%
-
Cadila: Rebound in domestic formulations to add to US sales, drive earnings
12.40 am | 9 Oct 2020 | Business Standard
In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages
-
Cadila Healthcare rises 4% on launch of pressurized Metered Dose Inhaler
10.48 am | 8 Oct 2020 | Business Standard
Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus' innovations in formulation technology
Quick Links for Cadila Healthcare:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices